de.mpg.escidoc.pubman.appbase.FacesBean
English
 
Help Guide Disclaimer Contact us Login
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders

MPS-Authors

Bauer,  M.
Max Planck Institute of Psychiatry, Max Planck Society;

Baur,  H
Max Planck Institute of Psychiatry, Max Planck Society;

Berghöfer,  A
Max Planck Institute of Psychiatry, Max Planck Society;

Ströhle,  A.
Max Planck Institute of Psychiatry, Max Planck Society;

Hellweg,  R
Max Planck Institute of Psychiatry, Max Planck Society;

Müller-Oerlinghausen,  B
Max Planck Institute of Psychiatry, Max Planck Society;

Baumgartner,  A
Max Planck Institute of Psychiatry, Max Planck Society;

Locator
There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Bauer, M., Baur, H., Berghöfer, A., Ströhle, A., Hellweg, R., Müller-Oerlinghausen, B., et al. (2002). Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. Journal of Affective Disorders, 68(2-3), 285-294.


Cite as: http://hdl.handle.net/11858/00-001M-0000-000E-A22D-5
Abstract
Background: Thyroxine (T-4) in supraphysiological doses has been found to be an effective supplemental treatment in open studies for refractory mood disorders. Unexpectedly, only minimal side effects have been reported. The goal of the present study was to investigate whether healthy controls and depressed patients differ in their ability to tolerate supraphysiological doses of T-4. Methods: This was an 8-week open study to investigate side effects and levels of thyroid hormones in 13 healthy controls and to compare results with those of 13 patients with refractory depression (unipolar and bipolar) undergoing the similar procedures and T-4 closing regimen in a previous augmentation study. Results: The rate of discontinuation due to side effects was significantly higher in the control group than for the patients (38% versus 0%). The severity of the side effects in the controls increased significantly during treatment with T-4. The side effect scores of the patients were higher than those of the controls prior to T-4 treatment, but did not change significantly during the treatment period. Although the serum concentrations of thyroid hormones rose significantly in both groups, concentrations of fT(3) and fT(4) were significantly higher in the controls. Conclusions: Healthy controls and depressed patients respond significantly differently to supraphysiological T-4 Healthy controls experience higher elevations of thyroid hormones in response to supraphysiological T-4 thus inducing significantly more side effects and discontinuation. Limitations: Open-label study; groups were studied at different times; in contrast to healthy controls, depressed patients were also taking antidepressants. Clinical relevance: Studies provide safety and tolerability data on treatment with supraphysiological doses of T-4. (C) 2002 Elsevier Science BV. All rights reserved